BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
土曜日, 9 26

SELLAS Life Sciences Group Inc

SLSNASDAQ
Trade with Public
Trade with Public
$11.61
-0.37-3.09%
近くで: Sep 25, 5:00 PM EST
$11.60
-0.01-0.09%
時間外: 7:59 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

SELLAS Life Sciences Gr Analyst Price Targets

Wall Street analyst price targets and consensus rating for SELLAS Life Sciences Gr (SLS).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOverweight# Analysts2Avg. Consensus PT$7Upside to Avg. PT-44.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Mar 12, 2026Maxim GroupJason McCarthyPT RaiseBuy$7→$10
Jul 16, 2025Maxim GroupJason McCarthyPT RaiseBuy$4→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Maintains Buy on SELLAS Life Sciences Gr, Raises Price Target to $7

Maxim Group analyst Jason McCarthy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and raises the price target from $4 to $7.
Benzinga Newsdesk

Galena Biopharma Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
Zacks

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and maintains $3 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and maintains $3 price target.
Benzinga Newsdesk

PRO
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8

Alliance Global Partners analyst James Molloy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and lowers the price target from $14 to $8.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6

Cantor Fitzgerald analyst Li Watsek maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and lowers the price target from $10 to $6.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved